Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform

What happened: Leads Biolabs presented updated first-in-human data at ESMO 2026 for LBL-034, its GPRC5D/CD3 bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma. Key numbers: Median PFS was 21.8 months in the 400 to 1,200 μg/kg dose range, with 56 patients enrolled and a median of 4.5 prior lines of therapy. 15-month and 18-month PFS rates were 62.0% and 54.8%. Why it matters: The company said the findings clinically validate its LeadsBody TCE platform and support development beyond hematologic malignancies, including autoimmune diseases and solid tumors.

Leads Biolabs presented updated first-in-human data at ESMO 2026 for LBL-034, its GPRC5D/CD3 bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma.

The company said the findings clinically validate its LeadsBody TCE platform and support development beyond hematologic malignancies, including autoimmune diseases and solid tumors.